arrow
E

Esper G. Kallás

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
H指数:64
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of Seasonal Trivalent Influenza Vaccine Formulated with Different Ratios (v/v) of Squalene-Containing IB160 Adjuvant in One- or Two-Vial Presentations

含不同比例(v/v)角鲨烯佐剂IB160的季三价流感疫苗在一支或两支瓶装中的表征

2026-09-090
OA
Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted influenza A (H5N8) vaccine

预大流行佐剂化A (H5N8)流感疫苗的安全性、体液和细胞免疫应答

Vaccine
IF3.5
2026-09-010
PRE
Phylodynamic reconstruction of H1N1pdm09 influenza virus transmission in Brazil: a decade of evolutionary dynamics

巴西H1N1pdm09流感病毒的传播系统发育动力学重建:十年进化动态

2026-01-290
OA
HIV serologic reactivity varies with time of ART initiation in persons on long-term ART

HIV血清学反应随长期接受ART治疗者ART起始时间的变化而变化

2025-12-010
PRE
Robust mission-driven responses to infectious disease threats delivered by the Abbott Pandemic Defense Coalition

雅培大流行防御联盟针对传染病威胁提供的稳健、任务驱动的应对措施

2025-10-310
OAAI
Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine

随机、双盲、安慰剂对照的III期临床试验,旨在证明3批简化版Butantan-dengue疫苗的批次间一致性。

Vaccine
IF3.5
2025-10-140
PRE
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial

灭活全病毒SARS-CoV-2疫苗(CoronaVac)在巴西医疗保健专业人员中的有效性和安全性:PROFISCOV试验

Vaccine
IF3.5
2025-07-310
PRE
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil

重组新城病病毒灭活疫苗表达SARS-CoV-2刺突蛋白的安全性及免疫原性:巴西随机疫苗对照的I期ADAPTCOV试验结果

VACCINE
IF3.5
2025-04-010
PRE
Enterovirus D68 Subgenotype B3 Circulation in Children with Acute Respiratory Illness in the State of Alagoas, Brazil
2025-02-110
OAAI
Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever Patients
2024-12-050
OA
Comprehensive molecular epidemiology of influenza viruses in Brazil: insights from a nationwide analysis
2024-11-230
OAAI
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Butantan-DV在2-59岁参与者中的疗效和安全性: 来自巴西的双盲,随机,安慰剂对照,3期,多中心试验的结果

2024-11-012
PRE
Unveiling viral pathogens in acute respiratory disease: Insights from viral metagenomics in patients from the State of Alagoas, Brazil
2024-09-232
OAAI
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine
2024-03-082
OAAI
Data-driven, cross-disciplinary collaboration: lessons learned at the largest academic health center in Latin America during the COVID-19 pandemic
2024-02-271
OAAI
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults
2024-02-0147
PRE